Better Outcomes from Autologous Transplants than Rituxan in Follicular Lymphoma

Autologous stem cell transplantation is linked to better survival outcomes in patients with follicular non-Hodgkin's lymphoma than any regimens featuring the monoclonal antibody Rituxan, according to findings from a multicenter study conducted chiefly by researchers from the British Columbia Cancer Agency.

Investigators sought to determine which transplant type (autologous or allogeneic) was best for patients diagnosed with transformed follicular non-Hodgkin's lymphoma, as well as whether either transplant type improved outcomes compared to Rituxan-based chemotherapy regimens.

In the study, the primary endpoint was Overall Survival (OS). There were three cohorts:

  1. Patients receiving an autologous stem cell transplantation (97 patients)
  2. Patients receiving an allogeneic stem cell transplantation (22 patients)
  3. Patients treated with rituximab regimens (53 patients)

The five-year overall survival rate, respectively, was found to be:

  1. 65 percent
  2. 46 percent
  3. 61 percent

The five-year progression-free survival rates were:

  1. 55 percent
  2. 46 percent
  3. 40 percent

Not surprisingly since the latter involves a host of additional potential problems, the five-year transplantation-related mortality rate was just five percent in the autologous cohort and 23 percent in the allogeneic group.

The team's findings have been published in the Journal of Clinical Oncology.

Source: JCO

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...